Treatment of chronic hepatitis C in nonresponders to interferon monotherapy.

P. Y. Kwo

Research output: Contribution to journalReview article

4 Scopus citations


Sixty percent of patients fail to respond to interferon monotherapy. African-Americans with hepatitis C appear to respond less well to interferon monotherapy. Retreatment with a higher dose of consensus interferon for 48 weeks has led to a sustained virologic response rate of 13%. As a group, interferon nonresponders who breakthrough while on interferon monotherapy seem to have a more favorable response rate to a repeat course of treatment. Retreatment with interferon and ribavirin for 6 months in nonresponders led to a sustained virologic response rate of 21%. Preliminary results from two trials in the United States demonstrate similar treatment efficacy. There is now evidence that maintenance interferon therapy may also be beneficial in interferon monotherapy nonresponders.

Original languageEnglish (US)
Pages (from-to)11-17
Number of pages7
JournalCurrent gastroenterology reports
Issue number1
StatePublished - Feb 2000


ASJC Scopus subject areas

  • Gastroenterology

Cite this